My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

460.46 +3.51 (+0.77%)
Official Closing Price Updated: 4:15 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 937,065
Open 460.28
Bid (Size) 441.19 (1)
Ask (Size) 461.38 (1)
Prev. Close 456.95
Today's Range 451.00 - 460.60
52wk Range 205.87 - 484.21
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the potential catalysts driving attention. 
Via Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute

Performance

YTD
+97.1%
+97.1%
1 Month
-1.9%
-1.9%
3 Month
+46.2%
+46.2%
6 Month
+93.7%
+93.7%
1 Year
+65.3%
+65.3%

More News

Read More
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout
Via Chartmill
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Via Benzinga
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
Via MarketMinute
Topics Artificial Intelligence Economy Government
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
Via Investor's Business Daily
Topics ETFs Government World Trade
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Via Benzinga
Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock
Via Benzinga
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
Via Benzinga
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics
Via Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
Via Benzinga
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 460.46
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 10/10/25 04:15 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 54.72B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 55B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.